{"nctId":"NCT02610231","briefTitle":"Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease","startDateStruct":{"date":"2015-12"},"conditions":["Idiopathic Parkinson's Disease"],"count":239,"armGroups":[{"label":"Istradefylline 20 mg or 40 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Istradefylline 20 mg or 40 mg"]}],"interventions":[{"name":"Istradefylline 20 mg or 40 mg","otherNames":["KW-6002"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Written informed consent;\n2. Subjects who completed Study No. 6002-014 inclusive of the 30-day follow-up period;\n3. Currently taking levodopa combination (carbidopa/levodopa or benserazide/levodopa) therapy plus at least one adjunctive PD medication;\n4. Women of child-bearing potential (WOCBP) must use a reliable method of contraception and have a negative serum pregnancy test at Screening;\n\nExclusion Criteria:\n\n1. Subjects with less than 70% treatment compliance throughout their enrollment on Study No 6002-014 and or with major protocol deviations in Study No. 6002-014 (subjects who failed to meet any of the inclusion criteria, subjects who met any of the exclusion criteria or subjects who met the criteria for subject withdrawal but who were not withdrawn);\n2. Subjects on apomorphine and/or dopamine receptor antagonists or direct gastrointestinal levodopa infusion;\n3. Subject who have had neurosurgical operation for PD;\n4. Subjects taking A2a antagonist, potent CYP3A4 inhibitors, potent CYP34A inducers;\n5. Subjects who have had a diagnosis of cancer or evidence of continued malignancy within the past three years (with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or in situ prostate cancer with normal prostate-specific antigens post resection).","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Evaluation of the Long-term Safety and Tolerability of Oral Istradefylline (20mg or 40mg/Day [mg/d])","description":"The number of subjects experiencing an adverse event as well as clinical laboratory tests (chemistry, haematology and urinalysis) were collected to evaluate the safety profile of istradefylline (20mg or 40mg/day \\[mg/d\\]).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null}]},{"measurements":[{"groupId":"OG000","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Global Impression - Overall Condition (Improvement by Study Visit) (ITT Analysis Set).","description":"The number and percentage of subjects showing improvement (moderate or mild) on PGI-I scores with Istradefylline 20 mg or 40 mg. Each subjects 'key symptom' (the symptom they had most trouble with) on the PGI-I was identified and evaluated at baseline and at Week 12, 26 and 52. In addition, the subject's overall condition and symptoms of fatigue, sleep and motivation to get things done were also evaluated at week 12, 26 and 52. Subjects rated each on a scale 1 to 5 for change from baseline status utilizing the following scale: 1= Moderate improvement (or greater) 2= Mild improvement, 3= No change from baseline, 4 = Mild deterioration, 5= Moderate deterioration (or greater).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null},{"groupId":"OG001","value":"109","spread":null},{"groupId":"OG002","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"95","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":30,"n":239},"commonTop":["Dyskinesia","Fall","Parkinson's disease"]}}}